Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

Gemcitabine 12Mitomycin 11Cisplatin 10Carboplatin 8pembrolizumab 7Docetaxel 4toripalimab 3avelumab 3atezolizumab 3Paclitaxel 3sacituzumab govitecan 2disitamab vedotin 2Taxes 2Specimen Handling 2Platinum 2Magnetic Resonance Spectroscopy 2Injections 21,2-diaminocyclohexaneplatinum II citrate 2vinflunine 1valrubicin 1tislelizumab 1lenvatinib 1eribulin 1epacadostat 1enfortumab vedotin 1durvalumab 1dodecyl maltoside 1Vitamin B 12 1Standard of Care 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Transitional Cell × valrubicin × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡